Literature DB >> 17589677

Cyclosporin A reduces airway mucus secretion and mucociliary clearance in rats.

Rogerio Pazetti1, Paulo Manuel Pego-Fernandes, Otavio Tavares Ranzani, Edwin Roger Parra, Geraldo Lorenzi-Filho, Fabio B Jatene.   

Abstract

PURPOSE: To assay the effects of cyclosporin A on mucus secretion from goblet cells and on mucociliary transport in situ in rats.
METHODS: Twenty-one male Wistar rats were assigned to 3 groups: control (n = 5), saline (n = 8), and cyclosporin A (n = 8). After 30 days of drug therapy, the rats were killed, and the lungs were removed from the thoracic cavity. Mucus samples were collected, and the transport rate was evaluated in vitro using a bullfrog palate model. Mucociliary transport was timed in situ by direct view of particles trapped on the mucus moving across the respiratory tract. Finally, the amount of stored mucins in the goblet cells of the respiratory epithelium was measured.
RESULTS: Drug dosage measurements showed that cyclosporine blood concentration at the moment the rats were killed was 1246.57 +/- 563.88 ng/mL. The in vitro transport rate was significantly lower (P < .001) in the cyclosporin A-treated group. Also, the in-situ mucociliary transport rate was decreased in all cyclosporin A-treated animals when compared to the saline group (P = .02). Mucus quantity measurements showed a significant decrease on both acid (P = .01) and neutral (P = .02) mucus production from goblet cells in the animals submitted to cyclosporin A therapy. The correlation between the percentage of total mucus and in vitro transport rate was positive and significant (r = 0.706, P < .001), as was the correlation between the percentage of total mucus and the in situ mucociliary transport rate (r = 0.688, P = .001).
CONCLUSION: This study shows that cyclosporin A plays an important role in the impairment of the mucociliary clearance in rats by reducing both acid and neutral mucus production from goblet cells and causing a decrease in the mucociliary transport velocity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17589677     DOI: 10.1590/s1807-59322007000300021

Source DB:  PubMed          Journal:  Clinics (Sao Paulo)        ISSN: 1807-5932            Impact factor:   2.365


  6 in total

Review 1.  Adverse effects of immunosuppressant drugs upon airway epithelial cell and mucociliary clearance: implications for lung transplant recipients.

Authors:  Rogerio Pazetti; Paulo Manuel Pêgo-Fernandes; Fabio Biscegli Jatene
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

2.  A pilot study to examine the effect of chronic treatment with immunosuppressive drugs on mucociliary clearance in a vagotomized murine model.

Authors:  Abhiram R Bhashyam; Peter J Mogayzel; Sharon McGrath-Morrow; Enid Neptune; Alla Malinina; James Fox; Beth L Laube
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

3.  The effects on mucociliary clearance of prednisone associated with bronchial section.

Authors:  Karina Andrighetti de Oliveira Braga; Natalia Aparecida Nepomuceno; Aristides Tadeu Correia; Fabio Biscegli Jatene; Paulo Manuel Pêgo-Fernandes
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

4.  Impact of topically-applied lpd-glucose on tracheal mucociliary clearance after warm and cold ischemia: short communication.

Authors:  Artur Eugênio de Azevedo-Pereira; Juliana Akemi Saka; Karina Andrighetti de Oliveira; Rogerio Pazetti; Paulo Manuel Pêgo-Fernandes; Fabio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

5.  Effects of mycophenolate sodium on mucociliary clearance using a bronchial section and anastomosis rodent model.

Authors:  Viviane Ferreira Paes E Silva; Rogerio Pazetti; Sonia de Fatima Soto; Mariana Moreira Quinhones Siqueira; Aristides Tadeu Correia; Fabio Biscegli Jatene; Paulo Manuel Pego-Fernandes
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

6.  Building a Lung Transplant Program.

Authors:  Marcos Naoyuki Samano; Paulo Manuel Pêgo-Fernandes
Journal:  Clinics (Sao Paulo)       Date:  2015-12       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.